Clinical trial
A Phase I Study of ExoFlo, an Ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease
NCT05130983 is registered in ClinicalTrials.gov with Direct Biologics, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of ExoFlo, an Ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease
- Lead sponsor
- Direct Biologics, LLC
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 23, 2023
- Completion date
- December 1, 2024
- Enrollment
- 3 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.